Idifarma Now Offers Spray Drying for Highly Potent Drugs

Idifarma, a Spanish contract development and manufacturing organization (CDMO) that specialises in niche and highly potent products, confirmed on Oct. 1, 2018 that its good manufacturing practice (GMP) spray drying technology for highly potent drugs is now operational.

The new equipment-GEA Niro Mobile Minor-has been installed and qualified in a dedicated area located at Idifarma’s European GMP plant, giving the company the capability to offer spray drying services for highly potent drugs up to category 4 OEL/OEB.

Commenting on the announcement, Luis Oquiñena, general manager and co-founder of Idifarma, stated in a press release, “This is the latest strategic investment for Idifarma and is driven by significant client demand as the market looks for spray drying solutions to improve the bioavailability of poorly soluble drugs. Idifarma is proud to support our customers’ spray drying projects at different scales and contribute to accelerated drug development and manufacturing timelines.”

With this latest news in addition to prior investments in serialization and capsule filling capabilities, the company has strengthened its position as a niche CDMO in the field of development and manufacture of oral solid-dosage forms.

“We recently reported another successful inspection by Spanish authorities, which means Idifarma will continue to offer EU GMP manufacturing and analytical services to our clients,” continued Oquiñena. “Combined with our continued investment in new technologies, this reflects our ongoing success within the CDMO market and our intent to further grow our business with specialized capabilities.”

Idifarma will be exhibiting its products and services at CPhI Worldwide, Stand 8B70, on Oct. 9–11, 2018 in Madrid Spain.

Source: Idifarma